Chloe Priya Rae Bhowmick, PH.D. Psychologist - Clinical Medicare: Medicare Enrolled Practice Location: 1291 W 12600 S Ste 102, Riverton, UT 84065 Phone: 801-272-5083 |
News Archive
The Financial Times reports on a legal dispute between the Indian government and the German pharmaceutical group Bayer, writing, "Bayer is appealing against the Indian patent controller's decision in March to override the company's monopoly on its cancer drug Nexavar, and to allow an Indian company to produce and sell the life-extending drug for just $173 a month - one-sixth of the $5,500 a month price charged by Bayer."
AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion.
If you're trying to lose weight, what are your chances of success? Your brain may hold the key.
Tumor cells divide fast. They thus require a high supply of components for their DNA, like purines. The biosynthesis of purines could now be a new point of attack for chemotherapy. However, without a natural model, the search for an inhibitor for a cellular process is like the proverbial search for a needle in a haystack. An American research team has developed a clever way to quickly conjure the desired "needle" out of the hay, presenting several candidates to act as starting points for the design of a purine synthesis inhibitor.
Policies allowing genes to be patented can make it more difficult for patients to access testing for important disease-causing gene mutations, according to a series of papers in a special online supplement published by Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.
› Verified 6 days ago